Responses

Download PDFPDF
The new nasogastric tubes: implications for neonatal practice
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Safe solution
    • Elisa Smit, Specialist Registrar Paediatrics
    • Other Contributors:
      • Louise Bridge, Cora Doherty

    Jamalpuri et al reported on the problems drawing up surfactant following recommendations from the National Patient Safety Agency (NPSA) to replace nasogastric tubes (1). They suggest using the old method of syringe and needle to draw up surfactant and transferring the content into a Penta syringe (Pentaferte, Campli, Italy) that can then be attached to the nasogastric tube. In response to this CM Kissack and Y Freer (2)...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    A response to "The new nasogastric tubes: implications for neonatal practice"

    We write in response to the letter from Jamalpuri et al (1) concerning the potential implications of the introduction of new nasogastric tubes in response to the National Patient Safety Agency Alert (2). This alert referred to the oral/enteral and intravenous routes but not to the tracheal route. It is likely that the NPSA were completely unaware of the impact of the alert on the administration of surfactant by this rou...

    Show More
    Conflict of Interest:
    None declared.